Hospital
Mclaren Lapeer Region
Mclaren Lapeer Region was paid $16.98M by Medicaid between Jan 2018 and Dec 2024, across 279 billing codes. Its largest line is 99285, emergency room visit (most serious) — 24% of everything it billed.
33Billing provider infoMCLAREN LAPEER REGION
LAPEER, MI 48446
LAPEER, MI 48446
33aNPI1205824737assigned 10/10/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$16.98M
24GClaims648,991
24DCodes billed279
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Michigan
Rank by total paid#51 of 86
Median peer was paid$21.55M
This provider vs. median0.8×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official KORTE, FRED controls 12+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 93,022 | $2.76M | |
| 2019 | 101,147 | $2.68M | |
| 2020 | 85,238 | $2.13M | |
| 2021 | 99,699 | $2.41M | |
| 2022 | 93,349 | $2.27M | |
| 2023 | 101,555 | $2.57M | |
| 2024incomplete | 74,981 | $2.17M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 24% | 12,038 | 11,106 | $4.10M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 21% | 20,214 | 18,745 | $3.65M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 11% | 15,749 | 15,029 | $1.84M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 6.5% | 12,394 | 11,317 | $1.10M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 4.6% | 5,082 | 4,865 | $784K |
| 96361 | Intravenous infusion, hydration; each additional hour | 3.0% | 12,732 | 11,136 | $508K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.7% | 3,185 | 3,043 | $295K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 1.7% | 11,883 | 9,987 | $295K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.7% | 3,956 | 3,758 | $290K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.7% | 12,193 | 2,550 | $286K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.6% | 10,153 | 8,866 | $271K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 1.5% | 3,712 | 3,648 | $256K |
267 more codes
| 71045 | Radiologic examination, chest; single view | 1.5% | 7,602 | $250K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.4% | 3,221 | $239K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.3% | 3,175 | $221K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | 1.2% | 360 | $205K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.2% | 1,906 | $200K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 4,377 | $149K |
| 82947 | <1% | 4,958 | $137K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 397 | $123K |
| 80061 | Lipid panel | <1% | 7,243 | $108K |
| G0378 | Hospital observation service, per hour | <1% | 2,887 | $98K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 180 | $89K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 1,686 | $86K |
| 76830 | Ultrasound, transvaginal | <1% | 1,498 | $83K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 1,743 | $82K |
| 93975 | <1% | 661 | $72K | |
| 59025 | Fetal non-stress test | <1% | 830 | $68K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 875 | $65K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 2,512 | $59K |
| 64635 | <1% | 68 | $54K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 4,583 | $54K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 740 | $43K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 280 | $43K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 96 | $41K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 412 | $39K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 1,616 | $38K |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | <1% | 1,041 | $35K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 266 | $35K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 199 | $34K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 1,498 | $33K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 669 | $33K |
| 76801 | <1% | 496 | $27K | |
| 97161 | <1% | 522 | $27K | |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 39 | $25K |
| 93971 | <1% | 386 | $20K | |
| 72110 | <1% | 720 | $18K | |
| 80053 | Comprehensive metabolic panel | <1% | 36,824 | $15K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 9,628 | $15K |
| 73564 | <1% | 1,145 | $13K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 985 | $12K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 6,577 | $12K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 91 | $12K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 37,656 | $12K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,006 | $11K |
| 73030 | <1% | 1,148 | $11K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 475 | $9K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 240 | $9K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 1,177 | $9K |
| 73610 | <1% | 1,163 | $9K | |
| 62323 | <1% | 30 | $9K | |
| 73630 | <1% | 1,404 | $9K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 458 | $8K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 9,620 | $8K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 2,205 | $7K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 8,846 | $7K |
| 71250 | <1% | 136 | $6K | |
| 94762 | <1% | 107 | $6K | |
| 73130 | <1% | 953 | $6K | |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | <1% | 199 | $6K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 5,153 | $5K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 738 | $5K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 700 | $5K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 123 | $5K |
| 97014 | <1% | 675 | $5K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 29,881 | $4K |
| 94060 | <1% | 64 | $4K | |
| 95816 | <1% | 42 | $4K | |
| 72131 | <1% | 127 | $4K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 553 | $4K |
| 82728 | <1% | 2,800 | $4K | |
| 74018 | <1% | 229 | $4K | |
| 20610 | <1% | 27 | $4K | |
| 86900 | <1% | 1,399 | $4K | |
| 73502 | <1% | 306 | $3K | |
| 84439 | <1% | 3,280 | $3K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 7,303 | $3K |
| 82607 | <1% | 2,931 | $3K | |
| 76775 | <1% | 81 | $3K | |
| 82746 | <1% | 2,514 | $3K | |
| 82670 | <1% | 457 | $3K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 2,124 | $3K |
| 84403 | <1% | 553 | $3K | |
| 90670 | <1% | 16 | $3K | |
| 83550 | <1% | 2,890 | $2K | |
| 71271 | <1% | 38 | $2K | |
| 97162 | <1% | 67 | $2K | |
| 73110 | <1% | 374 | $2K | |
| 83001 | <1% | 528 | $2K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 4,940 | $2K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 381 | $2K |
| 83540 | <1% | 3,162 | $2K | |
| 84146 | <1% | 442 | $2K | |
| 94799 | <1% | 4,544 | $2K | |
| 83735 | <1% | 9,931 | $2K | |
| G0008 | Administration of influenza virus vaccine | <1% | 125 | $2K |
| 84144 | <1% | 329 | $2K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 8,837 | $2K |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 358 | $2K |
| 83880 | <1% | 2,931 | $2K | |
| 84702 | <1% | 1,778 | $1K | |
| 76642 | <1% | 38 | $1K | |
| 83516 | <1% | 184 | $1K | |
| 70486 | <1% | 49 | $1K | |
| 72141 | <1% | 12 | $1K | |
| 85610 | <1% | 12,199 | $1K | |
| 76536 | <1% | 24 | $1K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 2,412 | $1K |
| 87070 | <1% | 1,839 | $1K | |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 69 | $941.52 |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 4,004 | $935.22 |
| 72050 | <1% | 25 | $921.53 | |
| 86140 | <1% | 1,765 | $885.41 | |
| 72128 | <1% | 13 | $868.99 | |
| 87077 | <1% | 1,905 | $783.38 | |
| 99195 | <1% | 12 | $777.48 | |
| 82248 | <1% | 525 | $770.81 | |
| 72072 | <1% | 24 | $764.39 | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 1,904 | $728.89 |
| 82627 | <1% | 142 | $715.94 | |
| 83690 | <1% | 8,721 | $634.29 | |
| 85027 | <1% | 2,311 | $630.39 | |
| 87186 | <1% | 1,667 | $619.51 | |
| 82247 | <1% | 356 | $572.51 | |
| 94760 | <1% | 3,854 | $540.80 | |
| 83655 | <1% | 311 | $515.20 | |
| 76770 | <1% | 12 | $493.06 | |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | <1% | 178 | $488.53 |
| 85730 | <1% | 6,746 | $476.03 | |
| 81025 | <1% | 10,078 | $473.64 | |
| 96367 | <1% | 43 | $411.71 | |
| 85652 | <1% | 1,514 | $411.13 | |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 440 | $388.91 |
| 81001 | <1% | 8,588 | $385.34 | |
| 84481 | <1% | 317 | $385.09 | |
| 86850 | <1% | 1,084 | $377.58 | |
| 84100 | <1% | 2,851 | $375.65 | |
| 90686 | <1% | 31 | $307.43 | |
| 81003 | <1% | 7,304 | $298.54 | |
| 90656 | <1% | 15 | $296.55 | |
| 82150 | <1% | 582 | $293.98 | |
| 90688 | <1% | 13 | $266.24 | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 114 | $261.83 |
| 87081 | <1% | 1,004 | $251.83 | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 14 | $242.65 |
| 80076 | <1% | 245 | $242.26 | |
| 74022 | <1% | 1,530 | $234.28 | |
| 73590 | <1% | 45 | $221.34 | |
| 82043 | <1% | 527 | $214.22 | |
| 82565 | <1% | 338 | $212.18 | |
| 73080 | <1% | 38 | $196.48 | |
| 93041 | <1% | 1,772 | $190.19 | |
| 82570 | <1% | 390 | $184.21 | |
| 72100 | <1% | 12 | $171.90 | |
| 80074 | <1% | 27 | $165.58 | |
| 86038 | <1% | 170 | $143.48 | |
| 83605 | <1% | 11,066 | $139.71 | |
| 84460 | <1% | 315 | $135.30 | |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 23 | $135.00 |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 16 | $129.68 |
| 83615 | <1% | 202 | $127.36 | |
| 84550 | <1% | 292 | $126.88 | |
| 82626 | <1% | 14 | $125.41 | |
| 84450 | <1% | 244 | $115.86 | |
| 87808 | <1% | 24 | $115.22 | |
| 86901 | <1% | 1,679 | $111.34 | |
| 87205 | <1% | 771 | $110.83 | |
| 82550 | <1% | 1,259 | $101.51 | |
| 87075 | <1% | 346 | $101.34 | |
| 83721 | <1% | 60 | $100.84 | |
| 70496 | <1% | 13 | $100.63 | |
| G0237 | Therapeutic procedures to increase strength or endurance of respiratory muscles, face to face, one on one, each 15 minutes (includes monitoring) | <1% | 15 | $97.68 |
| 87040 | <1% | 3,278 | $97.01 | |
| 87634 | <1% | 488 | $95.34 | |
| 84484 | <1% | 10,533 | $94.35 | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 2,346 | $85.50 |
| 92551 | <1% | 12 | $83.16 | |
| G0009 | Administration of pneumococcal vaccine | <1% | 32 | $80.52 |
| 84520 | <1% | 179 | $77.15 | |
| 82077 | <1% | 2,945 | $70.74 | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 54 | $64.38 |
| 85018 | <1% | 667 | $62.61 | |
| 85379 | <1% | 2,298 | $61.49 | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 290 | $57.04 |
| 87046 | <1% | 13 | $35.04 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 303 | $33.49 |
| A9270 | Non-covered item or service | <1% | 17,094 | $30.45 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 5,754 | $24.82 |
| 84703 | <1% | 488 | $24.26 | |
| 80143 | <1% | 852 | $23.17 | |
| 80179 | <1% | 787 | $23.17 | |
| 87427 | <1% | 13 | $22.23 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 281 | $22.07 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 749 | $22.00 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 13,780 | $19.84 |
| 82608 | <1% | 12 | $17.99 | |
| 87045 | <1% | 13 | $17.52 | |
| 86431 | <1% | 56 | $15.52 | |
| 88304 | <1% | 161 | $14.81 | |
| 86376 | <1% | 12 | $8.20 | |
| 81015 | <1% | 1,135 | $6.35 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,461 | $5.41 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 564 | $4.11 |
| J3490 | Unclassified drugs | <1% | 6,222 | $3.30 |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 899 | $3.16 |
| 85014 | <1% | 42 | $1.39 | |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 992 | $0.00 |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 0% | 39 | $0.00 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 0% | 470 | $0.00 |
| J1644 | Injection, heparin sodium, per 1000 units | 0% | 1,305 | $0.00 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | 0% | 12,409 | $0.00 |
| J2270 | Injection, morphine sulfate, up to 10 mg | 0% | 3,432 | $0.00 |
| 90461 | 0% | 624 | $0.00 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | 0% | 3,979 | $0.00 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | 0% | 605 | $0.00 |
| 90715 | 0% | 320 | $0.00 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 0% | 2,000 | $0.00 |
| 77003 | 0% | 25 | $0.00 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | 0% | 67 | $0.00 |
| 29125 | 0% | 68 | $0.00 | |
| J2300 | Injection, nalbuphine hydrochloride, per 10 mg | 0% | 16 | $0.00 |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | 0% | 28 | $0.00 |
| J0780 | Injection, prochlorperazine, up to 10 mg | 0% | 132 | $0.00 |
| 90681 | 0% | 15 | $0.00 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | 0% | 34 | $0.00 |
| 80305 | 0% | 309 | $0.00 | |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 26 | $0.00 |
| 64636 | 0% | 17 | $0.00 | |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 50 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 137 | $0.00 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | 0% | 12 | $0.00 |
| 99173 | 0% | 12 | $0.00 | |
| 94664 | 0% | 53 | $0.00 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 0% | 1,819 | $0.00 |
| 12001 | 0% | 133 | $0.00 | |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 2,121 | $0.00 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 5,097 | $0.00 |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 2,045 | $0.00 |
| 97010 | 0% | 2,566 | $0.00 | |
| J7050 | Infusion, normal saline solution, 250 cc | 0% | 1,807 | $0.00 |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 0% | 461 | $0.00 |
| J2704 | Injection, propofol, 10 mg | 0% | 1,801 | $0.00 |
| 96376 | 0% | 2,630 | $0.00 | |
| A9585 | Injection, gadobutrol, 0.1 ml | 0% | 744 | $0.00 |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | 0% | 552 | $0.00 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 633 | $0.00 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 1,651 | $0.00 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 0% | 5,734 | $0.00 |
| 87449 | 0% | 65 | $0.00 | |
| J2060 | Injection, lorazepam, 2 mg | 0% | 1,392 | $0.00 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 0% | 46 | $0.00 |
| 87390 | 0% | 12 | $0.00 | |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | 0% | 573 | $0.00 |
| 90723 | 0% | 14 | $0.00 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 0% | 130 | $0.00 |
| J1630 | Injection, haloperidol, up to 5 mg | 0% | 87 | $0.00 |
| 86702 | 0% | 12 | $0.00 | |
| 87807 | 0% | 19 | $0.00 | |
| 72170 | 0% | 26 | $0.00 | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | 0% | 76 | $0.00 |
| 12002 | 0% | 14 | $0.00 | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 0% | 13 | $0.00 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 0% | 57 | $0.00 |
| 86803 | 0% | 13 | $0.00 | |
| J0500 | Injection, dicyclomine hcl, up to 20 mg | 0% | 13 | $0.00 |
| J2470 | Injection, pantoprazole sodium, 40 mg | 0% | 36 | $0.00 |
| 86701 | 0% | 12 | $0.00 | |
| 96368 | 0% | 18 | $0.00 | |
| J1815 | Injection, insulin, per 5 units | 0% | 17 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialKORTE, FRED (VP/CFO)
| Provider | Location | Paid |
|---|---|---|
| Mclaren Flint | Flint, MI | $43.44M |
| Mclaren Flint | Flint, MI | $7.35M |
| Mclaren Lapeer Region | Lapeer, MI | $2.23M |
| Mclaren Flint | Flint, MI | $472K |
| Mclaren Flint | Flint, MI | $308K |
| Mclaren Flint | Flint, MI | $218K |
| Mclaren Flint | Flint, MI | $181K |
| Mclaren Flint | Flint, MI | $77K |
| Mclaren Flint | Flint, MI | $38K |
| Mclaren Lapeer Region | Lapeer, MI | $18K |
| Mclaren Lapeer Region | Lapeer, MI | $14K |
| Mclaren Lapeer Region | Lapeer, MI | $7K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.